Lisa A. Jackson, MD, MPH


“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine


Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine  safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

Recent publications

Markowitz LE, Hopkins RH Jr, Broder KR, Lee GM, Edwards KM, Daley MF, Jackson LA, Nelson JC, Riley LE, McNally VV, Schechter R, Whitley-Williams PN, Cunningham F, Clark M, Ryan M, Farizo KM, Wong HL, Kelman J, Beresnev T, Marshall V, Shay DK, Gee J, Woo J, McNeil MM, Su JR, Shimabukuro TT, Wharton M, Keipp Talbot H. COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic. Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.12.059. [Epub ahead of print]. PubMed

Irving SA, Groom HC, Belongia EA, Crane B, Daley MF, Goddard K, Jackson LA, Kauffman TL, Kenigsberg TA, Kuckler L, Naleway AL, Patel SA, Tseng HF, Williams JTB, Weintraub ES. Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.  Vaccine. 2023 Nov 22;41(48):7138-7146. doi: 10.1016/j.vaccine.2023.10.023. Epub 2023 Oct 20. PubMed

Cash-Goldwasser S, Reingold AL, Luby SP, Jackson LA, Frieden TR. Masks during pandemics caused by respiratory pathogens - evidence and implications for action. JAMA Netw Open. 2023;6(10):e2339443. doi: 10.1001/jamanetworkopen.2023.39443.  PubMed

Huang Y, Hejazi NS, Blette B, Carpp LN, Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Kenny A, Carone M, Huynh C, Miller J, El Sahly HM, Baden LR, Jackson LA, Campbell TB, Clark J, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB, On Behalf Of The Immune Assays, Moderna Inc, Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove, United States Government Usg/CoVPN Biostatistics Teams. Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial. Viruses. 2023 Sep 29;15(10):2029. doi: 10.3390/v15102029. PubMed

Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub +++. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.  Nat Med. 2023;29(9):2334-2346. doi: 10.1038/s41591-023-02503-4. Epub 2023 Aug 28.  PubMed

Irving SA, Crane B, Weintraub E, Kauffman TL, Brooks N, Patel SA, Razzaghi H, Belongia EA, Daley MF, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Kharbanda E, Klein NP, Zerbo O, Naleway AL. Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic. Obstet Gynecol. 2023 Sep 1;142(3):636-639. doi: 10.1097/AOG.0000000000005285. Epub 2023 Aug 3. PubMed

Kenigsberg TA, Goddard K, Hanson KE, Lewis N, Klein N, Irving SA, Naleway AL, Crane B, Kauffman TL, Xu S, Daley MF, Hurley LP, Kaiser R, Jackson LA, Jazwa A, Weintraub ES. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 Sep 7;41(39):5678-5682. doi: 10.1016/j.vaccine.2023.08.023. Epub 2023 Aug 19. PubMed

Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, McQuarrie LJ, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of a two dose regimen of Moderna mRNA Beta/Omicron BA.1 bivalent variant vaccine boost in a randomized clinical trial. J Infect Dis. 2023 Aug 10;jiad323. doi: 10.1093/infdis/jiad323. Online ahead of print. PubMed

Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z. PubMed

Kenigsberg TA, Hanson KE, Klein NP, Zerbo O, Goddard K, Xu S, Yih WK, Irving SA, Hurley LP, Glanz JM, Kaiser R, Jackson LA, Weintraub ES. Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.06.042. [Epub ahead of print]. PubMed




Clinical trial will evaluate mpox vaccine for adolescents

The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.

Volunteers needed


Researchers begin trial for mRNA flu vaccine

The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.



New study confirms safety of shingles vaccine

KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.



Gene-edited malaria vaccine shows promise

Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.

KPWHRI In the Media

Seattle-based clinical trial tweaks mRNA vaccines to fight COVID variants

Seattle NPR affiliate KUOW-FM, April 8, 2021